PHARMACEUTICAL ENTERPRISES

Company snapshot

Pharmaceutical Enterprises is a cGMP certified contract packer with a category A license. We specialize in blister packing and filling of solid dosage forms, redressing products for different markets and manufacturing of medical devices. We pack for the pharmaceutical, CAMS, Cosmetic & Veterinary health industries

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for PHARMACEUTICAL ENTERPRISES. Not investment advice.

• Peer + 0 momentum

  AbbVie

  TA overlap score 28.2

Recent activity

Latest pipeline, patent, and corporate events for PHARMACEUTICAL ENTERPRISES.

1. May 26, 2026 Clinical update

   APD334 — Phase 2

2. May 26, 2026 Clinical update

   APD334 — Phase 2

3. May 26, 2026 Clinical update

   Etrasimod — Phase 2

View all clinical trial activity →

• What is PHARMACEUTICAL ENTERPRISES?

  Arena Pharmaceutical Enterprises is a pharma organization headquartered in GB. Primary therapeutic focus areas include Primary Biliary Cholangitis, Pyoderma Gangrenosum, Ulcerative Colitis. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent record(s) to t

• Is PHARMACEUTICAL ENTERPRISES publicly traded?

  PHARMACEUTICAL ENTERPRISES appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does PHARMACEUTICAL ENTERPRISES develop or market?

  We link 1 drug profile(s) where PHARMACEUTICAL ENTERPRISES is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/arena-pharmaceutical-enterprises-limited#company-drugs.

• What are the latest developments for PHARMACEUTICAL ENTERPRISES?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does PHARMACEUTICAL ENTERPRISES focus on?

  PHARMACEUTICAL ENTERPRISES focuses on Primary Biliary Cholangitis, Pyoderma Gangrenosum, Ulcerative Colitis based on our analysis of their pipeline programs and drug development activities.